Navigation Links
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Date:2/16/2012

ases that affect fewer than 200,000 people in the U.S. Orphan designation qualifies the sponsor of the product for important tax credits, elimination of FDA license application fees and certain marketing incentives.

CSL Behring's rVIIa-FP was granted Orphan Drug Designations (ODD) by the European Commission in May, 2011.

About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective.  Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy. A complication in some patients is the development of inhibitory antibodies (inhibitors) to FVIII or FIX which renders replacement therapy ineffective.  This can occur in up to 25 percent of hemophilia A patients and around 5 percent of hemophilia B patients.  One treatment option for these patients is recombinant activated factor VII (called a bypassing agent) which can be used to achieve hemostasis without the need for factor VIII or IX. 

About the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
Preclinical studies have confirmed that CSL Behring's rVIIa-FP has favorable pharmacokinetic properties compared with the existing recombinant FVIIa product.
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
2. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
3. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
4. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
9. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
10. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... 1, 2015 Taiwan,s ... conference in Taipei on  August ... Vaucarrin™ platform, a targeted drug delivery technology that uses ... This event was part of a joint press conference held ... Inc. (GNT), showcasing GNT,s latest edible gold-based food and ...
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4
... 2012 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... The net loss for the first quarter ended ... of $16.0 million during the same period in 2011. The net ... one-time expense of $2.8 million for the purchase of a data ...
... 3, 2012  Gen-Probe Incorporated (NASDAQ: GPRO ) announced ... upcoming investor conferences previously announced on April 26, 2012, and ... conferences: , Deutsche Bank 37th Annual Health Care ... Time;  , Baird,s 2012 Growth Stock Conference in Chicago ...
Cached Medicine Technology:MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 5Gen-Probe Withdraws from Previously Announced Investor Presentations 2
(Date:9/1/2015)... ... 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... the LATINA Style 50 Report that recognizes companies that provide the best career opportunities ... BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for Latinas. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly ... Society for Dermatologic Surgery, according to a new survey that also offers insight ... Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... that creates negative pressure inside a wound to remove exudates, fluid, and infectious ... devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected ...
(Date:9/1/2015)... NJ (PRWEB) , ... September 01, 2015 , ... ... with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, ... for cancer patients. , Editorial and marketing groups within OncLive, which provides ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
... , , , , ... Jan. 28 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC ... manufacturer and supplier of pharmaceutical,products and medical nutrients addressing ... January 22, 2010 , its Board of Directors ...
... ... it has been selected by Central Garden & Pet Company (NASDAQ:CENT) as its sole ... ... the leading MSDS and chemical data management company, announced today that it has been ...
... ... data is much easier these days for Abba House – a 12-month ... Since partnering with Global Vision Technologies (GVT) and implementing FAMCare® – ... their data faster – giving them a clearer picture of how their ...
... ... against a disabled person. , ... San Jose, CA (PRWEB) January 28, 2010 -- Covidien, formerly Tyco Healthcare, with revenue in ... discriminated against and refused to hire a potential employee based solely on the fact that ...
... Vibrant ... arthritis pain relief blog. Painreliefcream.info provides news, updates and information on arthritis and joint ... ... the sponsorship of http://www.painreliefcream.info/ a specialty arthritis pain relief blog. Painreliefcream.info provides ...
... ... international events for Valentine,s weekend in Las Vegas: The USA ... the Power Pilates "Power Higher" Conference will host Pilates professionals worldwide. ... teams, Pilates professionals and thousands of spectators from around the world ...
Cached Medicine News:Health News:Biostar Pharmaceuticals, Inc. Announces Change of Auditor 2Health News:Biostar Pharmaceuticals, Inc. Announces Change of Auditor 3Health News:Central Garden & Pet Selects SiteHawk as Its MSDS Management Provider 2Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 2Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 3Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 4Health News:Covidien Sued By Samuelson, Wilson and Roe for Disability Discrimination 2Health News:Covidien Sued By Samuelson, Wilson and Roe for Disability Discrimination 3Health News:Vibrant Health Co Sponsors Specialty Arthritis Pain Relief Blog, painreliefcream.info 2Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 2Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 3Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 4Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 5
... volume Finnpipette Techpette combines form ... performance pipette. Advanced pipetting technology, ... ensures quality, safety, comfort and ... volume range is an important ...
Inquire...
... ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, ... 100-1000 Inaccuracy (%) ... Imprecision(%) ... 10 Dimensions: ...
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
Medicine Products: